Showing results (181-190 of 279) with videos related to

Sort By:
Pageof 28
Acta Oncologica (Stockholm, Sweden)|May 10, 2008
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancerBent Kristensen, Bent Ejlertsen, Henning T Mouridsen, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|July 23, 2019
Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based studyElham Hedayati, Antroula Papakonstantinou, Sofie A M Gernaat, et al.
Oncogene|July 12, 2018
Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell typesAnders P Mutvei, Sebastian K-J Landor, Rhys Fox, et al.
Breast Cancer Research : BCR|March 2, 2019
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumoursArian Lundberg, Linda S Lindström, Jingmei Li, et al.
The Oncologist|September 23, 2017
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior TherapyKyriaki Tzogani, Jorge Camarero Jiménez, Isabel Garcia, et al.
Nature Communications|December 6, 2018
Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencingMichael Bartoschek, Nikolay Oskolkov, Matteo Bocci, et al.
IEEE Journal of Biomedical and Health Informatics|June 12, 2024
Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology ImagesNikos Tsiknakis, Georgios Manikis, Evangelos Tzoras, et al.
Oncotarget|September 17, 2015
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implicationsSiker Kimbung, Anikó Kovács, Anna Danielsson, et al.
Cancers|October 5, 2019
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast CancerIoannis Zerdes, Majken Wallerius, Emmanouil G Sifakis, et al.
Acta Oncologica (Stockholm, Sweden)|December 23, 2010
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Nils-Olof Bengtsson, Lena Carlsson, et al.
Pageof 28